A new survey commissioned by Leo Pharma confirms there’s plenty of room in the market for its chronic hand eczema treatment ...

LEO Pharma A/S, a global leader in medical dermatology, today presented late-breaking data showcasing responses in a subgroup of patients from the DELTA 1 and 2 trials at the 83 rd American Academy of ...

Sixty-five percent of dermatology providers surveyed agree there is a lack of education and understanding of chronic hand ...

Danish dermatology specialist LEO Pharma could be just weeks away from EU approval for delgocitinib, a treatment for chronic hand eczema (CHE) considered to be its top pipeline prospect.

Researchers have found in DELTA China trial that delgocitinib cream (Anzupgo) 20 mg/g significantly reduces severity of ...

"2024 was a year of strong progress for LEO Pharma with double-digit growth in sales and another year of significantly improved EBITDA. A major highlight in 2024 was the approval ...

BALLERUP, Denmark--(BUSINESS WIRE)--LEO Pharma A/S, a global leader in medical dermatology, today presented late-breaking data showcasing responses in a subgroup of patients from the DELTA 1 and 2 ...

LEO Pharma will host a symposium, “Chronic Hand Eczema: A New Day Is at Hand,” at 7 p.m. ET on March 6 at the Hyatt Regency Orlando ahead of the American Academy of Dermatology (AAD ...

An Ipsos survey commissioned by LEO Pharma Inc. reveals dermatology providers believe there is a lack of awareness and understanding of chronic hand eczema as a condition separate from eczema ...